VJHemOnc is committed to improving our service to you

ASH 2019 | abTCD haploidentical HSCT in pediatric AL: long-term outcomes

VJHemOnc is committed to improving our service to you

Annalisa Ruggeri

Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, outlines the follow-up analysis of the long-term outcome of children with acute leukemia (AL) given alpha-beta T and B-cell depleted HLA-haploidentical hematopoietic stem cell transplantation (TBdepl-haploHSCT). Data from this follow-up confirms in a larger population that TBdepl-haploHSCT is a safe and effective transplant option, being associated with a low risk of both non-relapse mortality and acute/chronic GvHD. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter